Evidence map›Paper›PMID 32493230›Full record

ArticleBMC cancer2020

Clinical association of progesterone receptor isoform A with breast cancer metastasis consistent with its unique mechanistic role in preclinical models.

Rayna Rosati, Kailey Oppat, Yanfang Huang, Seongho Kim, Manohar Ratnam

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Rayna RosatiBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 840.1, Detroit, MI, 48201-2013, USA.
Kailey OppatBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 840.1, Detroit, MI, 48201-2013, USA.
Yanfang HuangBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 840.1, Detroit, MI, 48201-2013, USA.
Seongho KimBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 840.1, Detroit, MI, 48201-2013, USA.
Manohar RatnamBarbara Ann Karmanos Cancer Institute and Department of Oncology, Wayne State University School of Medicine, 4100 John R, HWCRC 840.1, Detroit, MI, 48201-2013, USA. ratnamm@karmanos.org.ORCID http://orcid.org/0000-0002-2866-7136
Wayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLuminal breast cancer (L-BCa) comprises the majority of incurable, distally metastatic breast cancer cases. Estrogen supports growth of L-BCa cells but suppresses invasiveness. Estrogen also induces the progesterone receptor (PR). Invasiveness and metastasis of L-BCa cells is supported by the short PR isoform (PR-A), in response to the range of pre- and post-menopausal plasma hormone levels, by counteracting the effects of estrogen via micro RNA-mediated cross-talk with the estrogen receptor (ER). PR-B directly supports L-BCa invasion and metastasis and also inhibits tumor growth, both only at high progesterone levels. As public datasets on L-BCa tumors cannot distinguish PR-A, this study was designed to seek clinical evidence for the role of PR-A in metastasis in comparison with PR-B and ER.

methodsMeasurement of tumor PR-A, PR-B and ER mRNA expression in 125 treatment-naive primary L-BCa patients with differential node involvement and analysis using linear mixed effects models. Transcriptional activity assays of PR-A and PR-B.

resultsLymph node involvement was strongly associated with PR-A expression (median, 3-fold higher vs. node-negative), independent of age, pathologic type, tumor grade, HER2 and PR-B. PR-B and ER correlated weakly with PR-A, but whereas PR-B and the PR-A/PR-B ratio were not significantly associated with node involvement, ER weakly negatively correlated with node positivity. PR-A was hypersensitive to mifepristone compared with PR-B.

conclusionsTaken together with previous mechanistic studies, the findings provide clinical evidence in support of the role of PR-A in L-BCa metastasis. They also suggest the possibility of developing selective PR-A modulators for future interventions in appropriate clinical situations.

Indexed as

AdultAgedAged, 80 and overBreastBreast NeoplasmsCell Line, TumorEstrogensFemaleGene Expression ProfilingHumansLymphatic MetastasisLymph NodesMiddle AgedNeoplasm InvasivenessProspective StudiesProtein IsoformsEstrogensprogesterone receptor Aprogesterone receptor BProtein IsoformsReceptors, EstrogenReceptors, ProgesteroneBreast cancerEstrogenEstrogen receptorMifepristoneProgesteroneProgesterone receptor

Identifiers

PMID32493230
PMCPMC7268268
OpenAlexW3032827286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.